Tibric acid: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description|A synthetic compound used in lipid-lowering therapy}} | |||
{{Use dmy dates|date=October 2023}} | |||
== | ==Overview== | ||
Tibric | '''Tibric acid''' is a [[synthetic compound]] that has been investigated for its potential use in [[lipid-lowering therapy]]. It belongs to the class of [[fibrate]] drugs, which are primarily used to reduce [[cholesterol]] levels and [[triglycerides]] in the blood. Tibric acid functions by activating [[peroxisome proliferator-activated receptors]] (PPARs), which play a crucial role in the regulation of [[lipid metabolism]]. | ||
== | ==Mechanism of Action== | ||
Tibric acid exerts its effects by binding to and activating PPAR-alpha, a type of nuclear receptor. This activation leads to an increase in the expression of genes involved in [[fatty acid oxidation]], [[lipoprotein lipase]] activity, and the reduction of [[apolipoprotein C-III]], which inhibits lipoprotein lipase. As a result, there is an enhanced breakdown of triglycerides and a reduction in the levels of [[very low-density lipoprotein]] (VLDL) and [[low-density lipoprotein]] (LDL) cholesterol. | |||
== | ==Clinical Use== | ||
Although tibric acid has shown potential in preclinical studies, its clinical use has been limited. The development of tibric acid as a therapeutic agent was halted due to concerns about its [[hepatotoxicity]] and the potential for [[carcinogenicity]] observed in animal studies. As a result, it has not been approved for use in humans. | |||
== | ==Side Effects== | ||
The primary concern with tibric acid is its potential to cause liver damage. Studies in rodents have shown that high doses of tibric acid can lead to liver enlargement and the development of liver tumors. These findings have raised significant safety concerns, preventing its approval for clinical use. | |||
== | ==Chemical Structure== | ||
[[File:Tibric_acid.svg|thumb|right|Chemical structure of Tibric acid]] | |||
Tibric acid is characterized by its unique chemical structure, which includes a [[carboxylic acid]] group that is essential for its activity as a fibrate. The structure of tibric acid allows it to interact with PPAR-alpha, facilitating its lipid-lowering effects. | |||
[[ | ==Research and Development== | ||
[[ | Research into tibric acid has provided valuable insights into the mechanisms of fibrate drugs and their effects on lipid metabolism. Despite its lack of approval, tibric acid has contributed to the understanding of PPAR activation and its role in lipid regulation. | ||
[[Category: | |||
[[Category: | ==Related Pages== | ||
* [[Fibrate]] | |||
* [[Cholesterol]] | |||
* [[Triglyceride]] | |||
* [[Peroxisome proliferator-activated receptor]] | |||
* [[Lipid metabolism]] | |||
[[Category:Lipid-lowering agents]] | |||
[[Category:Carboxylic acids]] | |||
Latest revision as of 03:41, 13 February 2025
A synthetic compound used in lipid-lowering therapy
Overview[edit]
Tibric acid is a synthetic compound that has been investigated for its potential use in lipid-lowering therapy. It belongs to the class of fibrate drugs, which are primarily used to reduce cholesterol levels and triglycerides in the blood. Tibric acid functions by activating peroxisome proliferator-activated receptors (PPARs), which play a crucial role in the regulation of lipid metabolism.
Mechanism of Action[edit]
Tibric acid exerts its effects by binding to and activating PPAR-alpha, a type of nuclear receptor. This activation leads to an increase in the expression of genes involved in fatty acid oxidation, lipoprotein lipase activity, and the reduction of apolipoprotein C-III, which inhibits lipoprotein lipase. As a result, there is an enhanced breakdown of triglycerides and a reduction in the levels of very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) cholesterol.
Clinical Use[edit]
Although tibric acid has shown potential in preclinical studies, its clinical use has been limited. The development of tibric acid as a therapeutic agent was halted due to concerns about its hepatotoxicity and the potential for carcinogenicity observed in animal studies. As a result, it has not been approved for use in humans.
Side Effects[edit]
The primary concern with tibric acid is its potential to cause liver damage. Studies in rodents have shown that high doses of tibric acid can lead to liver enlargement and the development of liver tumors. These findings have raised significant safety concerns, preventing its approval for clinical use.
Chemical Structure[edit]
Tibric acid is characterized by its unique chemical structure, which includes a carboxylic acid group that is essential for its activity as a fibrate. The structure of tibric acid allows it to interact with PPAR-alpha, facilitating its lipid-lowering effects.
Research and Development[edit]
Research into tibric acid has provided valuable insights into the mechanisms of fibrate drugs and their effects on lipid metabolism. Despite its lack of approval, tibric acid has contributed to the understanding of PPAR activation and its role in lipid regulation.
